RenovoRx Announces Presentation At Symposium On Clinical Interventional Oncology Highlighting TAMP For Targeted Treatment Of Locally Advanced Pancreatic Cancer On Saturday, September 21, 2024
RenovoRx Announces Presentation At Symposium On Clinical Interventional Oncology Highlighting TAMP For Targeted Treatment Of Locally Advanced Pancreatic Cancer On Saturday, September 21, 2024
Dr. Gandhi will also discuss the status of the Company's ongoing Phase III TIGeR-PaC study, which is evaluating the use of the TAMP therapy platform with gemcitabine HCl in patients with LAPC. Additionally, he will review a recent publication in the international peer-reviewed journal, The Oncologist, of early-stage clinical data on the intra-arterial administration of gemcitabine HCl utilizing the TAMP including Phase I/II dose escalation safety study (RR1) and acquired data from a post-marketing post-treatment observational registry study (RR2).RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Ripal Gandhi, M.D., FSIR, FSVM will present at the Symposium on Clinical Interventional Oncology ("CIO") which is being held September 20-22, 2024, at the Loews Hotel in Miami Beach, Florida. Dr. Gandhi's presentation will highlight RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer ("LAPC") and recent publications of clinical data.
RenovoRx, Inc.（「RenovoRx」或「公司」）（納斯達克：RNXT）是一家臨床階段的生物製藥公司，基於局部藥物傳遞平台開發新型精準腫瘤治療方法。該公司今天宣佈，Ripal Gandhi博士將在2024年9月20-22日在洛斯安吉納斯洛斯酒店（Loews Hotel）舉辦的臨床介入腫瘤學研討會（CIO）上發表演講。演講將重點介紹RenovoRx的TAMP（經動脈微灌注）治療平台，用於治療局部晚期胰腺癌（LAPC）和近期的臨床數據發表。
Dr. Gandhi, professor of Interventional Radiology at the Miami Cancer Institute and Miami Cardiac and Vascular Institute, Florida International University Herbert Wertheim College of Medicine, is a Course Director for the Symposium on CIO. Since 2018, Dr. Gandhi has been instrumental as a principal investigator for the Miami Cancer Institute in RenovoRx's pivotal ongoing Phase III TIGeR-PaC clinical trial in LAPC.
Gandhi博士是邁阿密癌症研究所（Miami Cancer Institute）和邁阿密心臟和血管研究所（Miami Cardiac and Vascular Institute）的介入放射學教授，也是佛羅里達國際大學赫伯特·沃爾特海姆醫學學院的課程主任。自2018年以來，Gandhi博士一直是的RenovoRx在LAPC的關鍵進行中的III期TIGeR-PaC臨床試驗的首席研究員。
Dr. Gandhi's presentation will provide an overview of the clinical challenges of the standard of care treatment available to LAPC patients. Systemic (intravenous) chemotherapy, while considered the standard-of-care for LAPC, is often associated with debilitating side effects, and may have limited effectiveness in treating this type of cancer due to tumors lacking dedicated blood vessels critical for delivering chemotherapy. Dr. Gandhi will highlight the TAMP therapy platform and the opportunity it may give to LAPC patients as a potential targeted oncology option for treatment.
Gandhi博士的演講將概述目前提供給LAPC患者的標準治療方法所面臨的臨床挑戰。全身性（靜脈）化療雖然被認爲是LAPC的標準治療，但常常伴有副作用，而且在治療此類癌症時有效性有限，因爲腫瘤缺乏輸送化療所必需的血管。Gandhi博士將重點介紹TAMP治療平台及其對LAPC患者的潛在靶向腫瘤治療選擇的機會。
Dr. Gandhi will also discuss the status of the Company's ongoing Phase III TIGeR-PaC study, which is evaluating the use of the TAMP therapy platform with gemcitabine HCl in patients with LAPC. Additionally, he will review a recent publication in the international peer-reviewed journal, The Oncologist, of early-stage clinical data on the intra-arterial administration of gemcitabine HCl utilizing the TAMP including Phase I/II dose escalation safety study (RR1) and acquired data from a post-marketing post-treatment observational registry study (RR2).
Gandhi博士還將討論公司正在進行的III期TIGeR-PaC研究的進展情況，該研究評估了TAMP治療平台與鹽酸吉西他濱在LAPC患者中的應用。此外，他還將回顧國際同行評議期刊《腫瘤學家》上有關TAMP的靜脈內給藥的早期臨床數據的最近發表情況，包括I/II期劑量遞增安全性研究（RR1）和後市場治療後觀察性登記研究（RR2）的獲得數據。
譯文內容由第三人軟體翻譯。